Insider Selling: Penumbra, Inc. (NYSE:PEN) EVP Sells $172,458.00 in Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00. Following the completion of the transaction, the executive vice president now owns 66,539 shares in the company, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Penumbra Trading Down 0.9 %

Shares of PEN stock opened at $275.07 on Friday. The firm has a 50-day moving average price of $267.39 and a 200 day moving average price of $235.14. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of 809.01, a PEG ratio of 2.83 and a beta of 0.53. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Research analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PEN. True Wealth Design LLC acquired a new position in Penumbra in the 3rd quarter valued at about $26,000. UMB Bank n.a. raised its stake in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares during the last quarter. Hurley Capital LLC acquired a new position in shares of Penumbra during the 4th quarter valued at about $56,000. Huntington National Bank increased its stake in shares of Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after acquiring an additional 154 shares during the last quarter. Finally, Mather Group LLC. increased its stake in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after acquiring an additional 208 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on PEN. Oppenheimer initiated coverage on shares of Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Penumbra in a research report on Wednesday, February 19th. Royal Bank of Canada boosted their target price on shares of Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. JPMorgan Chase & Co. boosted their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Finally, Truist Financial boosted their target price on shares of Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.